Every so often, clinical tries are said to ‘fail’, but can the trial actually fail? According to John Lechleiter, President and CEO of Eli Lilly and Company, “a clinical trial is a failure only if we can’t learn from it.” He believes that no matter how a clinical...
Enrollment barriers to secure patients for genomically matched trials still challenge the discovery for molecular cancer therapies; however , help may be on the way. Only a few patients who have gene alterations are selected to participate in genomically matched...
According to a report by the Institute of Medicine (IOM), the National Cancer Institute’s (NCI) Clinical Trials Cooperative Group program was inefficient, underfunded, and filled with red tape. The NCI program contains 3,100 institutions in the U.S., Canada, and...
